Louis W. Sullivan Sells 26,209 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Louis W. Sullivan sold 26,209 shares of the stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the transaction, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Price Performance

UTHR opened at $359.58 on Friday. The firm has a market capitalization of $16.05 billion, a price-to-earnings ratio of 15.79, a PEG ratio of 1.05 and a beta of 0.54. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The business has a 50 day simple moving average of $371.01 and a two-hundred day simple moving average of $344.37.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm’s revenue was up 22.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.38 earnings per share. As a group, sell-side analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Argus lifted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Jefferies Financial Group upped their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. TD Cowen lifted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, The Goldman Sachs Group upped their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $370.86.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently modified their holdings of the stock. Meiji Yasuda Asset Management Co Ltd. lifted its holdings in United Therapeutics by 1.6% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock worth $652,000 after buying an additional 33 shares during the period. Toronto Dominion Bank lifted its stake in shares of United Therapeutics by 0.8% in the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock valued at $1,441,000 after purchasing an additional 37 shares during the period. ClariVest Asset Management LLC boosted its position in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its stake in United Therapeutics by 14.0% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 42 shares during the period. Finally, First Citizens Bank & Trust Co. raised its holdings in United Therapeutics by 1.8% in the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 48 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.